Jean-Charles Soria: Cancer remains the dominant focus of drug developers
Jean-Charles Soria, Oncology Therapeutic Area Head at Amgen, shared a post on X:
“2024 FDA approvals show that cancer remains the dominant focus of drug developers, with 15 (30%) novel approvals in 2024.
Dermatology and non-malignant hematology were second, with 6 (12%) approvals each.
A total of 32 (64%) of the new approvals are small molecules, in line with the 5-year average for this leading modality.”
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023